Clinical Study to Evaluate the Possible Efficacy and Safety of Fexofenadine in Patients With Parkinson's Disease Treated With Conventional Treatment
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
Parkinson's disease (PD) is a chronic, progressive neurological disorder characterized by both motor and non-motor symptoms. PD is the second most common neurodegenerative disorder after Alzheimer's disease and the most common movement disorder. PD has age-related pathology; it is present in 1-2% of the population over 60 years of age. The disease is characterized by a triad of disordered voluntary motor activity in the form of bradykinesia (slowness of movement) or even akinesia (absence of movement),rigidity and postural instability, and a resting tremor of the hands and less commonly the feet.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 70
Healthy Volunteers: f
Locations
Other Locations
Egypt
Tanta University
RECRUITING
Tanta
Contact Information
Primary
Ihab Elsayed Hassan, Doctor
ihassan@horus.edu.eg
0201067831661
Time Frame
Start Date: 2024-12-10
Estimated Completion Date: 2026-12-20
Participants
Target number of participants: 46
Treatments
Active_comparator: control arm
will receive their standard dopamine replacement therapy for 6 months.
Active_comparator: Fexofenadine group
will receive Fexofenadine 180 mg once daily together with their standard dopamine replacement therapy for 6 months
Related Therapeutic Areas
Sponsors
Leads: Tanta University